Publications

– Oncolytic viruses influence the biogenesis and immunogenicity of tumor-derived extracellular vesicles. Hirigoyen U, Boisgerault N. Med Sci (Paris). 2025 Nov;41(11):866-868.

– Development of potent Affitin-based bispecific NK cell engagers for the therapy of MSLN-expressing cancers. Briolay T*, Petithomme T*, Gravoueille H, Fresquet J, Lambot S, Cossard P, Mouratou B, Fortun A, Bernardeau K, Quéméner A, Maillasson M, Boisgerault N, Mortier E, Davodeau F, Pecorari P*, and Blanquart C*. Mol Ther Oncol. 2025.

– Intratumour, anatomical and temporal heterogeneity in mesothelioma. Arnould M, Neilly MDJ, Blyth KG, Jean D. Thorax. 2025 Oct 31:thorax-2024-222052

– Antitumor immuno-virotherapy with attenuated strains of measles virus. Fonteneau JF, Boisgerault N, Tangy F. Virologie (Montrouge). 2025 Aug 18;29(4):271-291.

– Narciclasine as a Novel Treatment for Lung Cancer and Malignant Pleural Mesothelioma: Insights from 3D Tumor Spheroid Models. Jiang S, Berkcan S, Perriraz-Mayer N, Triponez F, Serre-Beinier V. Int J Mol Sci. 2025 Oct 17

– Pharmacogenomic Characterization of a Large Cohort of Patient-Derived Cell Lines Identifies Therapeutic Strategies for Pleural Mesothelioma. Assié JB, Meiller C, Stern E, Lasvergnas J, Arnould M, Pan L, Montagne F, Sequeiros R, Al Zreibi C, Del Nery E, Genovesio A, Lantuejoul S, Le Pimpec-Barthes F, Zucman-Rossi J, Jaurand MC, Blanquart C, Wald O, Jean D.  Cancer Res. 2025 Sep 24. 

– New soluble CSF-1R-dimeric mutein with enhanced trapping of both CSF-1 and IL-34 reduces suppressive tumor-associated macrophages in pleural mesothelioma. Joalland N, Quéméner A, Deshayes S, Humeau R, Maillasson M, LeBihan H, Salama A, Fresquet J, Remy S, Mortier E*, Blanquart C*, Guillonneau C*, Anegon I*. J Immunother Cancer. 2025 Mar 17;13(3):e010112.

– The impact of Charcot-Leyden Crystal protein on mesothelioma chemotherapy: targeting eosinophils for enhanced chemosensitivity. Willems M, Hamaidia M, Fontaine A, Grégoire M, Halkin L, Vilanova Mañá L, Terres R, Jamakhani M, Deshayes S, Brostaux Y, Heinen V, Louis R, Duysinx B, Jean D, Wasielewski E, Scherpereel A, Blanquart C, Willems L. EBioMedicine. 2024 Nov;109:105418.
 
– Interplay between oncolytic measles virus, macrophages and cancer cells induces a proinflammatory tumor microenvironment. Chatelain C, Berland L, Grard M, Jouand N, Fresquet J, Nader J, Hirigoyen U, Petithomme T, Combredet C, Pons-Tostivint E, Fradin D, Treps L, Blanquart C, Boisgerault N, Tangy F, Fonteneau JF. Oncoimmunology. 2024 Jul 10;13(1):2377830.
 

– Specific Targeting of Mesothelin-Expressing Malignant Cells Using Nanobody-Functionalized Magneto-Fluorescent Nanoassemblies. Briolay T, Fresquet J, Meyer D, Kerfelec B, Chames P, Ishow E, Blanquart C. Int J Nanomedicine. 2024 Jan 20;19:633-650.

– Oncolytic viruses alter the biogenesis of tumor extracellular vesicles and influence their immunogenicity. Hirigoyen U, Guilbaud C, Krejbich M, Fouet M, Fresquet J, Arnaud B, Com E, Pineau C, Cadiou G, Burlaud-Gaillard J, Erbs P, Fradin D, Labarrière N, Fonteneau JF, Petithomme T, Boisgerault N. Molecular Therapy: Oncology. 2024. 32(4). 

– Preclinical evaluation of CDK4 phosphorylation predicts high sensitivity of pleural mesotheliomas to CDK4/6 inhibition. Paternot S, Raspé E, Meiller C, Tarabichi M, Assié JB, Libert F, Remmelink M, Bisteau X, Pauwels P, Blum Y, Le Stang N, Tabone-Eglinger S, Galateau-Sallé F, Blanquart C, Van Meerbeeck JP, Berghmans T, Jean D, Roger PP. Mol Oncol. 2024 Apr;18(4):866-894.
 

– Krebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma. Stockhammer P, Baumeister H, Ploenes T, Bonella F, Theegarten D, Dome B, Pirker C, Berger W, Hegedüs L, Baranyi M, Schuler M, Deshayes S, Bölükbas S, Aigner C, Blanquart C, Hegedüs B. Lung Cancer. 2023 Nov;185:107360.

– Multiomic analysis of malignant pleural mesothelioma identifies molecular axes and specialized tumor profiles driving intertumor heterogeneity. Mangiante L, Alcala N, Sexton-Oates A, Di Genova A, Gonzalez-Perez A, Khandekar A, Bergstrom EN, Kim J, Liu X, Blazquez-Encinas R, Giacobi C, Le Stang N, Boyault S, Cuenin C, Tabone-Eglinger S, Damiola F, Voegele C, Ardin M, Michallet MC, Soudade L, Delhomme TM, Poret A, Brevet M, Copin MC, Giusiano-Courcambeck S, Damotte D, Girard C, Hofman V, Hofman P, Mouroux J, Cohen C, Lacomme S, Mazieres J, de Montpreville VT, Perrin C, Planchard G, Rousseau N, Rouquette I, Sagan C, Scherpereel A, Thivolet F, Vignaud JM, Jean D, Ilg AGS, Olaso R, Meyer V, Boland-Auge A, Deleuze JF, Altmuller J, Nuernberg P, Ibáñez-Costa A, Castaño JP, Lantuejoul S, Ghantous A, Maussion C, Courtiol P, Hernandez-Vargas H, Caux C, Girard N, Lopez-Bigas N, Alexandrov LB, Galateau-Salle F, Foll M, Fernandez-Cuesta L. Nat Genet. 2023 Apr;55(4):607-618.

– Defining and targeting tumor-associated macrophages in malignant mesothelioma. Wu L, Kohno M, Murakami J, Zia A, Allen J, Yun H, Chan M, Baciu C, Liu M, Serre-Beinier V, De Palma M, Felley-Bosco E, Yeung J, Pugh TJ, de Perrot M. Proc Natl Acad Sci U S A. 2023 Feb 28
 

– Excess of blood eosinophils prior to therapy correlates with worse prognosis in mesothelioma. Willems M, Scherpereel A, Wasielewski E, Raskin J, Brossel H, Fontaine A, Grégoire M, Halkin L, Jamakhani M, Heinen V, Louis R, Duysinx B, Hamaidia M, Willems L. Front Immunol. 2023 Mar 21;14:1148798.

 – ChemR23 activation reprograms macrophages toward a less inflammatory phenotype and dampens carcinoma progression. Lavy M, Gauttier V, Dumont A, Chocteau F, Deshayes S, Fresquet J, Dehame V, Girault I, Trilleaud C, Neyton S, Mary C, Juin P, Poirier N, Barillé-Nion S, Blanquart C. Front Immunol. 2023 Jul 19;14:1196731.
 
– Oncolytic attenuated measles virus encoding NY-ESO-1 induces HLA I and II presentation of this tumor antigen by melanoma and dendritic cells. Grard M, Idjellidaine M, Arbabian A, Chatelain C, Berland L, Combredet C, Dutoit S, Deshayes S, Dehame V, Labarrière N, Fradin D, Boisgerault N, Blanquart C, Tangy F, Fonteneau JF. Cancer Immunol Immunother. 2023 Oct;72(10):3309-3322.
 
 
 

– Viral Mimicry Response Is Associated With Clinical Outcome in Pleural Mesothelioma. Sun S, Qi W, Rehrauer H, Ronner M, Hariharan A, Wipplinger M, Meiller C, Stahel R, Früh M, Cerciello F, Fonteneau JF, Jean D, Felley-Bosco E. JTO Clin Res Rep. 2022 Nov 7;3(12):100430.

–A Community-Driven, Openly Accessible Molecular Pathway Integrating Knowledge on Malignant Pleural Mesothelioma. Martens M, Kreidl F, Ehrhart F, Jean D, Mei M, Mortensen HM, Nash A, Nymark P, Evelo CT, Cerciello F.

Front Oncol. 2022 Apr 26;12:849640.

 – HDAC Inhibition with Valproate Improves Direct Cytotoxicity of Monocytes against Mesothelioma Tumor Cells. Hoyos C, Fontaine A, Jacques JR, Heinen V, Louis R, Duysinx B, Scherpereel A, Wasielewski E, Jamakhani M, Hamaidia M, Willems L.Cancers (Basel). 2022 Apr 26;14(9):2164.
 
 – Heterogeneous RNA editing and influence of ADAR2 on mesothelioma chemoresistance and the tumor microenvironment. Hariharan A, Qi W, Rehrauer H, Wu L, Ronner M, Wipplinger M, Kresoja-Rakic J, Sun S, Oton-Gonzalez L, Sculco M, Serre-Beinier V, Meiller C, Blanquart C, Fonteneau JF, Vrugt B, Rüschoff JH, Opitz I, Jean D, de Perrot M, Felley-Bosco E. Mol Oncol. 2022 Dec;16(22):3949-3974.
 
– IL-7 is expressed in malignant mesothelioma and has a prognostic value. Mai HL, Deshayes S, Nguyen TV, Dehame V, Chéné AL, Brouard S, Blanquart C. Mol Oncol. 2022 Oct;16(20):3606-3619.
 
– KRAS signaling in malignant pleural mesothelioma. Marazioti A, Krontira AC, Behrend SJ, Giotopoulou GA, Ntaliarda G, Blanquart C, Bayram H, Iliopoulou M, Vreka M, Trassl L, Pepe MAA, Hackl CM, Klotz LV, Weiss SAI, Koch I, Lindner M, Hatz RA, Behr J, Wagner DE, Papadaki H, Antimisiaris SG, Jean D, Deshayes S, Grégoire M, Kayalar Ö, Mortazavi D, Dilege Ş, Tanju S, Erus S, Yavuz Ö, Bulutay P, Fırat P, Psallidas I, Spella M, Giopanou I, Lilis I, Lamort AS, Stathopoulos GT. EMBO Mol Med. 2022 Feb 7;14(2):e13631.